Julia L. Douvas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia L. Douvas has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Espeland
Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA 02115, USA
1 shared publication - Grace Godwin
Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA 02115, USA
1 shared publication - Jennifer Nicoloro-SantaBarbara
Department of Psychiatry Brigham and Women's Hospital Boston Massachusetts USA
1 shared publication - Julia Middlesworth
Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA 02115, USA
1 shared publication - Mariana Castells
Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA 02115, USA
1 shared publication - Matthew P. Giannetti
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts
1 shared publication
Latest Publications
- Open Access
- 5 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (2) , 123
Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis
Mastocytosis is a myeloproliferative neoplasm characterized by abnormal proliferation and activation of clonal mast cells typically bearing the KITD816V mutation. Symptoms manifest due to the release of bioactive mediators and the tissue infiltration by neoplastic mast cells. Mast cell activation symptoms include flushing, pruritus, urticaria, abdominal cramping, diarrhea, wheezing, neuropsychiatric symptoms, and anaphylaxis. Up to 50% of patients with mastocytosis report a history of provoked and unprovoked anaphylaxis, with Hymenoptera venom and drugs the most common culprits. NSAIDs, antibiotics, vaccines, perioperative medications, and radiocontrast media are often empirically avoided without evidence of reactions, depriving patients of needed medications and placing them at risk for unfavorable outcomes. The purpose of this review is to highlight the most common agents responsible for adverse drug reactions in patients with mastocytosis, with a review of current epidemiology, diagnosis, and management of drug hypersensitivity and Hymenoptera venom allergy.
- 5 January 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (2) , 123
Open AccessChallenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis
Mastocytosis is a myeloproliferative neoplasm characterized by abnormal proliferation and activation of clonal mast cells typically bearing the KITD816V mutation. Symptoms manifest due to the release of bioactive mediators and the tissue infiltration by neoplastic mast cells. Mast cell activation symptoms include flushing, pruritus, urticaria, abdominal cramping, diarrhea, wheezing, neuropsychiatric symptoms, and anaphylaxis. Up to 50% of patients with mastocytosis report a history of provoked and unprovoked anaphylaxis, with Hymenoptera venom and drugs the most common culprits. NSAIDs, antibiotics, vaccines, perioperative medications, and radiocontrast media are often empirically avoided without evidence of reactions, depriving patients of needed medications and placing them at risk for unfavorable outcomes. The purpose of this review is to highlight the most common agents responsible for adverse drug reactions in patients with mastocytosis, with a review of current epidemiology, diagnosis, and management of drug hypersensitivity and Hymenoptera venom allergy.